# A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

> **NCT05744921** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 202 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** Pozelimab
- **DRUG:** Cemdisiran

## Key facts

- **NCT ID:** NCT05744921
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-07
- **Primary completion:** 2029-02-26
- **Final completion:** 2029-02-26
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05744921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05744921, "A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05744921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*